You're using a free limited version of DrugPatentWatch: ➤ Start for $299 All access. No Commitment.

Last Updated: December 17, 2025

Details for New Drug Application (NDA): 216755


✉ Email this page to a colleague

« Back to Dashboard


NDA 216755 describes LIKMEZ, which is a drug marketed by Saptalis Pharms and is included in one NDA. It is available from two suppliers. There are two patents protecting this drug. Additional details are available on the LIKMEZ profile page.

The generic ingredient in LIKMEZ is metronidazole. There are eighteen drug master file entries for this compound. Seventy-one suppliers are listed for this compound. Additional details are available on the metronidazole profile page.
Summary for 216755
Tradename:LIKMEZ
Applicant:Saptalis Pharms
Ingredient:metronidazole
Patents:2
Pharmacology for NDA: 216755
Medical Subject Heading (MeSH) Categories for 216755
Anti-Infective Agents
Antiprotozoal Agents
Radiation-Sensitizing Agents
Suppliers and Packaging for NDA: 216755
Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
LIKMEZ metronidazole SUSPENSION;ORAL 216755 NDA Saptalis Pharmaceuticals, LLC 71656-066 71656-066-20 200 mL in 1 BOTTLE (71656-066-20)
LIKMEZ metronidazole SUSPENSION;ORAL 216755 NDA Saptalis Pharmaceuticals, LLC 71656-066 71656-066-75 75 mL in 1 BOTTLE (71656-066-75)

Profile for product number 001

Active Rx/OTC/Discontinued:RXDosage:SUSPENSION;ORALStrength500MG/5ML
Approval Date:Sep 22, 2023TE:RLD:Yes
Patent:⤷  Get Started FreePatent Expiration:Oct 4, 2039Product Flag?YSubstance Flag?Delist Request?
Patent:⤷  Get Started FreePatent Expiration:Jan 16, 2039Product Flag?YSubstance Flag?Delist Request?
Patented Use:TREATMENT OF AMEBIASIS IN ADULTS AND PEDIATRIC PATIENTS
Patent:⤷  Get Started FreePatent Expiration:Jan 16, 2039Product Flag?YSubstance Flag?Delist Request?
Patented Use:TREATMENT OF ANAEROBIC BACTERIAL INFECTIONS IN ADULTS

Complete Access Available with Subscription

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

 
© Copyright 2002-2025 thinkBiotech LLC
ISSN: 2162-2639
Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Major Patent Expirations 2025 - 2026
 NCE-1 Patent Challenge Dates 2025 - 2026
Preferred Citation:

Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2025, www.DrugPatentWatch.com.
   See Primary Research Papers Citing DrugPatentWatch

Links